FDA Approves Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Subcutaneous Use in Generalized Myasthenia Gravis

SAN DIEGO, June 20, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ( " Halozyme " ) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news